Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

The five-year funding, totalling US$7M, has been awarded by the Leducq Foundation as part of its International Networks of Excellence Programme. The aim of this programme is to bring together teams of researchers from around the world with complementary expertise and resources. They will work to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and neurovascular disease.

The work is due to start on 1 January 2022, with the European part of the network coordinated by Professor Alastair Buchan from the University of Oxford's Radcliffe Department of Medicine (RDM). He will work closely with Professor Russell Foster from the Sleep and Circadian Neuroscience Institute in the Nuffield Department of Clinical Neurosciences and Professor David Ray from the Oxford Centre for Diabetes, Endocrinology and Metabolism (RDM). Other participating institutions include the University of Munich, Stanford University, Harvard University, University of California, Los Angeles, and the Carlos III Health Institute and Hosptial 12 Octubre in Madrid.

The network aims to identify novel targets for stroke therapy based on circadian biology. Researchers will achieve this by defining circadian mechanisms at the brain-vascular interface, and immune, cardiovascular and metabolic systems in experimental stroke models. They will confirm and extend findings in cell and animal models with genetic, imaging, outcome, and biomarker analyses in stroke patients.

This trans-Atlantic network brings together basic, translational and clinical scientists with inter-disciplinary expertise in molecular biology, neurobiology, immunology, cardiovascular biology, circadian biology, imaging, genetics, biomarkers and clinical trials. The network will mentor and develop early career scientists through an exchange of Leducq fellows between labs, a journal club and annual summer schools. This network is uniquely positioned to discover new science, change the way stroke research is conducted, and train the next generation of stroke scientists for inter-disciplinary and translational research.

Similar stories

New Research Highlights Importance of Early Years Development on Future Wellbeing

Oxford researchers involved nearly 4,000 children across the UK in three specially developed science lessons to educate pupils about brain development during early childhood. The SEEN (Secondary Education around Early Neurodevelopment) project was commissioned and funded by KindredSquared and is part of a wider drive to increase public understanding of how early experiences can shape the adults we become.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

Oxfordshire Young People Involved in Childline Research Project

New research conducted by the Neuroscience, Ethics and Society group and NeurOX Young People’s Advisory Group in the Department of Psychiatry at the University of Oxford, and the NSPCC, has looked at how Childline’s message boards help support young people.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.